Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
4,16 USD | 0,00% | -6,09% | -30,55% |
Attività
Numero di dipendenti: 536
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Oral Small Molecule and Protein Therapeutics
100,0
%
| 271 | 100,0 % | 331 | 100,0 % | +22,37% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
87,0
%
| - | - | 288 | 87,0 % | - |
Non-United States
11,4
%
| - | - | 38 | 11,4 % | - |
Global
1,6
%
| 271 | 100,0 % | 5 | 1,6 % | -98,00% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 01/01/07 |
Anthony Doyle
DFI | Director of Finance/CFO | 44 | 02/04/20 |
Ryan Arnold
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/22 |
Helen Thackray
CTO | Chief Tech/Sci/R&D Officer | 55 | 20/09/19 |
Philip George
PRN | Corporate Officer/Principal | - | 01/09/22 |
Corporate Officer/Principal | - | 01/01/15 | |
Charles Gayer
PRN | Corporate Officer/Principal | 53 | 01/08/15 |
Human Resources Officer | - | 01/11/18 | |
Salisa Hauptmann
LAW | General Counsel | - | 01/01/21 |
Corporate Officer/Principal | 61 | 01/01/23 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Alan Levin
BRD | Director/Board Member | 62 | 27/02/20 |
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 01/01/07 |
Director/Board Member | 60 | 26/07/21 | |
Stephen Aselage
BRD | Director/Board Member | 73 | 04/01/19 |
Director/Board Member | 69 | 10/10/11 | |
Nancy Hutson
CHM | Chairman | 74 | 20/01/12 |
Helen Thackray
CTO | Chief Tech/Sci/R&D Officer | 55 | 20/09/19 |
Steven Galson
BRD | Director/Board Member | 67 | 01/09/21 |
Theresa Heggie
BRD | Director/Board Member | 63 | 03/12/18 |
Amy McKee
BRD | Director/Board Member | 52 | 20/09/21 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 206 330 603 | 199 798 093 ( 96,83 %) | 0 | 96,83 % |
Coordinate società
BioCryst Pharmaceuticals, Inc.
4505 Emperor Boulevard Suite 200
27703-8457, Durham
+919 859 1302
http://www.biocryst.comSettore
Vendite per regione
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
-30,55% | 858 Mln | |
-2,31% | 103 Mrd | |
+0,56% | 95,28 Mrd | |
+1,69% | 22,15 Mrd | |
-17,37% | 21,02 Mrd | |
-9,30% | 18,15 Mrd | |
-41,01% | 16,73 Mrd | |
-14,85% | 16,05 Mrd | |
+3,21% | 13,68 Mrd | |
+33,54% | 12,17 Mrd |
- Borsa valori
- Azioni
- Azione BCRX
- Società BioCryst Pharmaceuticals, Inc.